跳至主要内容
临床试验/CTRI/2024/01/061649
CTRI/2024/01/061649
尚未招募
3 期

Prevalence and impact of sarcopenia and frailty in inflammatory bowel disease, and the effect of multi-modal interventions on sarcopenia and clinical outcomes in patients with inflammatory bowel disease - NI

All India Institute of Medical Sciences0 个研究点目标入组 0 人待定

概览

阶段
3 期
干预措施
未指定
疾病 / 适应症
Health Condition 1: K509- Crohns disease, unspecifiedHealth Condition 2: K519- Ulcerative colitis, unspecified
发起方
All India Institute of Medical Sciences
状态
尚未招募
最后更新
2年前

概览

简要总结

暂无简介。

注册库
who.int
开始日期
待定
结束日期
待定
最后更新
2年前
研究类型
Interventional

研究者

入排标准

入选标准

  • Inclusion Criteria (First phase)
  • 1\)Age between 18 years to 65 years
  • 2\)Patients with aggressive IBD as defined above
  • 3\)Provide informed consent
  • Inclusion Criteria (Second phase)
  • 1\)Patients found to be having sarcopenia during first phase of the study randomized into intervention arm and standard treatment arm
  • 2\)Provide informed consent

排除标准

  • Exclusion Criteria (First phase)
  • 1\)Patients with other comorbid illnesses (end stage liver, kidney, cardiac illnesses, neuromuscular illnesses and terminal cancer patients)
  • 2\)Pregnancy and Lactation
  • Exclusion Criteria (Second phase)
  • 1\)Patients with other comorbid illnesses (end stage liver, kidney, cardiac illnesses, neuromuscular illnesses and terminal cancer patients)
  • 2\)Pregnancy and lactation
  • 3\)Inability to perform exercise
  • 4\)Inability to adhere to prescribed diet / nutritional supplements
  • 5\)Patients requiring surgery
  • 6\)Patients enrolled in other trials

结局指标

主要结局

未指定

相似试验